Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Epithelial sodium channel subunit gamma (SCNN1G) is a pore-forming subunit of the epithelial sodium channel (ENaC), an amiloride-sensitive, non-voltage-gated ion channel crucial for sodium reabsorption across epithelial tissues. The ENaC complex, assembled as a heterotrimer of alpha, beta, and gamma subunits, is essential for regulating sodium and water balance in the kidney, lung, and other epithelia, affecting blood volume and blood pressure. Mutations in SCNN1G cause rare monogenic hypertension (Liddle syndrome) and hypotension (pseudohypoaldosteronism type I) syndromes and contribute to common blood pressure variation and cardiovascular risk. ENaC function is targeted by drugs (notably amiloride) used to treat hypertension and fluid overload. The channel is regulated by hormones such as aldosterone and is expressed in tissues including kidney tubules, airway epithelia, distal colon, and taste buds, where it also plays a role in salt perception.
Blockade of sodium conductance via ENaC by direct binding (blocker/antagonist) – e.g., by amiloride
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epithelial sodium channel subunit gamma (SCNN1G).